FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/08/2026
Back to search
Official data from USPTO
ENDOPORE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ENDOPORE
ST13
US500000079379326Class
5, 35, 42, 44
Filing
79379326
Registration
7805555
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
41
Latest update
04/03/2026
Trademark type
Word
Nice classes
5, 35, 42, 44
Filing date
07/25/2023
Registration date
05/27/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/27/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
HARMON, RAYMOND E
Law office
L30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
VITARKA THERAPEUTICS LTD
Representatives
Jordan Arnot Leahey CM Law PLLC
Technical classification
Nice Classes
Class 5Class 35Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for intracellular delivery of drugs for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of drugs for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for gene editing; veterinary preparations for gene editing; pharmaceutical preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of therapeutic substances for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases focused on non-viral delivery technology; veterinary preparations for intracellular delivery of therapeutic substances for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical preparations for intracellular delivery of nucleic acids for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of nucleic acids for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of proteins for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of proteins for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery of small molecules for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; veterinary preparations for intracellular delivery of small molecules for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of drugs for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for gene editing; pharmaceutical substances for intracellular delivery of therapeutic substances focused on the development of RNA therapies for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of therapeutic substances for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases focused on non-viral delivery technology; pharmaceutical substances for intracellular delivery of nucleic acids for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of proteins for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical preparations for intracellular delivery peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of peptides for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical substances for intracellular delivery of small molecules for the treatment of cancertumoursneuropathic painneurological diseases and neurodegenerative diseases; pharmaceutical compositions and preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer
Class 35
Compilation of information into computer databases in the medical field
Class 42
Scientific and technological servicesscientific researchtechnological researchresearch and designall in the fields of intracellular delivery of drugsgene editingintracellular delivery of therapeutic substances focused on the development of RNA therapiesintracellular delivery of therapeutic substances focused on non-viral delivery technologyintracellular delivery of nucleic acidsintracellular delivery of proteinsintracellular delivery of peptidesintracellular delivery of small molecules; research services in the fields of intracellular delivery of drugsgene editingintracellular delivery of therapeutic substances focused on the development of RNA therapiesintracellular delivery of therapeutic substances focused on non-viral delivery technologyintracellular delivery of nucleic acidsintracellular delivery of proteinsintracellular delivery of peptidesintracellular delivery of small molecules; clinical trialsscientific research in the nature of conducting clinical trials for others; development of pharmaceutical preparations and medicines; laboratory research services relating to pharmaceuticals; medical research laboratories; medical research laboratory services; medical research; medical research services; pharmaceutical drug development services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of vaccines and medicines; research of pharmaceuticals; research relating to medicines; research relating to pharmaceuticals; scientific investigations for medical purposes; scientific research and development; scientific research in the field of pharmacy; medical researchservices for assessing the efficacy of pharmaceuticals; informationadvisory and consultancy services relating to all of the aforesaid
Class 44
Medical services; medical analysis for the diagnosis and treatment of persons; pharmacy advicepreparation of prescriptions in pharmacies and providing medical advice related to pharmaceutics; advisory services relating to health; advisory services relating to medical services; health carearranging of medical treatment; consultancy relating to health care; health advice and information services; health care; health care services; health centres being health clinic services; health clinic services; information services relating to health care; medical information retrieval services; health caremedical treatment services; medical health assessment services; health carepreparation of reports relating to health care matters; professional consultancy relating to health; providing health information; provision of health care services; provision of medical services; provision of medical information relating to medical practitioners; provision of medical information relating to medical specialists; services for the provision of medical care information; informationadvisory and consultancy services relating to all of the aforesaid
Publications
History of USPTO decisions and trademark events.
41 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/21/2025
FIMP
FINAL DISPOSITION PROCESSED
12/21/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/27/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/27/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
05/27/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/08/2025
PUBO
PUBLISHED FOR OPPOSITION
04/08/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/02/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/14/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
03/14/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/14/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
03/14/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/14/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/08/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/20/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/20/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
01/15/2025
LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
11/14/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
10/14/2024
GNFR
FINAL REFUSAL E-MAILED
10/14/2024
CNFR
FINAL REFUSAL WRITTEN
10/14/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/10/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/10/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/10/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/10/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
09/10/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
09/10/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/10/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/10/2024
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
08/02/2024
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
07/19/2024
RFNT
REFUSAL PROCESSED BY IB
05/08/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/17/2024
RFRR
REFUSAL PROCESSED BY MPU
04/17/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/31/2024
CNRT
NON-FINAL ACTION WRITTEN
03/30/2024
DOCK
ASSIGNED TO EXAMINER
03/27/2024
MAFR
APPLICATION FILING RECEIPT MAILED
09/26/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/22/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/21/2023
Continuous trademark protection
Get notified about every new filing that threatens ENDOPORE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.